The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A sequential therapy with sorafenib followed by regorafenib against single-line atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC): Indirect treatment comparisons (ITC) using the RESORCE study.

Jamie  Partridge

Employment - Bayer HealthCare Pharmacuticals

Stock and Other Ownership Interests  - Abbott Laboratories

Other Relationship - New York University (NYU)

David  Aceituno

Consulting or Advisory Role - Bayer (Inst); Eisai (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst)

Noman  Paracha

Employment - Bayer

Stock and Other Ownership Interests  - Bayer

Howard  Thom

Consulting or Advisory Role - Argenx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lundbeck (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst); Roche (Inst)